Rule 4.7B

Appendix 4C – 3rd Quarter

Quarterly Report for Entities Admitted on the Basis of Commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of Entity:

Antisense Therapeutics Limited

ABN:

41 095 060 745

Quarter Ended ('Current Quarter')

31st March 2015

Consolidated Statement of Cash Flows

Cash Flows Related to Operating Activities		**Current Quarter $A'000**	**Year-to-Date (9 months) $A'000**
1.1	Receipts from customers	-	-
1.2	Payments for:		
	(a) staff costs (including R&D staffing costs)	(237)	(723)
	(b) advertising/marketing/investor relations	(34)	(133)
	(c) research and development (excluding R&D staffing costs)	(321)	(1,158)
	(d) leased assets	-	-
	(e) other working capital	(282)	(676)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	17	32
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Other (R&D Tax Concession refund)	-	1,140
Net Operating Cash Flows		**(857)**	**(1,518)**

+ See chapter 19 for defined terms.

		Current Quarter $A'000	Year-to-Date (9 months) $A'000
1.8	**Net Operating Cash Flows (carried forward)**	**(857)**	**(1,518)**
Cash Flows Related to Investing Activities			
1.9	Payment for acquisition of:		
	(a) businesses (item)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets		-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (provide details if material)	-	-
Net Investing Cash Flows		**-**	**-**
1.14	**Total Operating and Investing Cash Flows**	**(857)**	**(1,518)**
Cash Flows Related to Financing Activities			
1.15	Proceeds from issues of shares, options, etc.	6	1,929
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings	-	(50)
1.19	Dividends paid	-	-
1.20	Other (Capital Raising Costs/ Borrowing costs)	-	(195)
Net Financing Cash Flows		**6**	**1,684**
Net Increase / (Decrease) in Cash Held		**(851)**	**166**
1.21	Cash at beginning of quarter/year to date	2,351	1,334
1.22	Exchange rate adjustments to item 1.21	-	-
1.23	**Cash at End of Quarter ***	**1,500**	**1,500**

* Note: It is anticipated that based on the Company's expected R&D expenditure to 30 June 2015 that the Company is to receive an R&D Tax incentive refund later in the CY15 of approx. $700k or more.

+ See chapter 19 for defined terms.

Payments to Directors of the Entity and Associates of the Directors
Payments to Related Entities of the Entity and Associates of the Related Entities

		Current Quarter $A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	134
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Item 1.24 Reflects amounts paid to directors including director's fees, salaries, superannuation, bonuses and consulting fees (excluding reimbursements).

Non-Cash Financing and Investing Activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

-

Financing Facilities Available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount Available $A'000	Amount Used $A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Reconciliation of Cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		**Current Quarter $A'000**	**Previous Quarter $A'000**
4.1	Cash on hand and at bank	300	251
4.2	Deposits at call	1,200	2,100
4.3	Bank overdraft	-	-
4.4	Other - Bank Guarantee / Trust	-	-
Total: Cash at End of Quarter (item 1.23)		**1,500**	**2,351**

Acquisitions and Disposals of Business Entities

		Acquisitions ***(Item 1.9(a))***	**Disposals** ***(Item 1.10(a))***
5.1	Name of entity	-	-
5.2	Place of incorporation or registration	-	-
5.3	Consideration for acquisition or disposal	-	-
5.4	Total net assets	-	-
5.5	Nature of business	-	-

Compliance statement

1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

2 This statement does give a true and fair view of the matters disclosed.



Sign Here: _____

Print Name: **Phillip Hains**
Company Secretary

Date: Thursday 30th April 2015

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.

2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.

3. **Accounting Standards.** ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.